ANG1009

O=C([C@@H](NC(CCCC(O[C@@H]1[C@H]([C@]2([H])O[C@H](C)OC[C@]2(O[C@H]1O[C@H](C3=CC4=C(C=C3[C@H]([C@]56[H])C7=CC(OC)=C(OC(CN(C)C)=O)C(OC)=C7)OCO4)[C@]5(COC6=O)[H])[H])O)=O)=O)[C@@H](C)O)N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CC8=CC=C(O)C=C8)=O)CCC(O)=O)=O)CCC(O)=O)=O)[C@@H](C)O)=O)CCCCNC(CCCC(O[C@@H]9[C@H]([C@]%10([H])O[C@H](C)OC[C@]%10(O[C@H]9O[C@H](C%11=CC%12=C(C=C%11[C@H]([C@]%13%14[H])C%15=CC(OC)=C(OC(CN(C)C)=O)C(OC)=C%15)OCO%12)[C@]%13(COC%14=O)[H])[H])O)=O)=O)=O)CC%16=CC=CC=C%16)=O)CC(N)=O)=O)CC(N)=O)=O)CCCNC(N)=N)=O)CCCCNC(CCCC(O[C@@H]%17[C@H]([C@]%18([H])O[C@H](C)OC[C@]%18(O[C@H]%17O[C@H](C%19=CC%20=C(C=C%19[C@H]([C@]%21%22[H])C%23=CC(OC)=C(OC(CN(C)C)=O)C(OC)=C%23)OCO%20)[C@]%21(COC%22=O)[H])[H])O)=O)=O)=O)=O)CCCNC(N)=N)=O)CO)=O)=O)=O)CC%24=CC=C(O)C=C%24)=O)CC%25=CC=CC=C%25)=O)CC%26=CC=CC=C%26

[1]Ché C, et al. New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J Med Chem. 2010 Apr 8;53 (7) :2814-24.